Ligand Pharmaceuticals Incorporated
General ticker "LGND" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.2B (TTM average)
Ligand Pharmaceuticals Incorporated follows the US Stock Market performance with the rate: 56.7%.
Estimated limits based on current volatility of 1.9%: low 293.18$, high 304.55$
Factors to consider:
- Total employees count: 47 (-30.9%) as of 2025
- Top business risk factors: Supply chain disruptions, Regulatory and compliance, IP infringement, Market acceptance, Acquisition/divestiture risks
- Current price 45.5% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [135.79$, 203.06$]
- 2026-12-31 to 2027-12-31 estimated range: [132.81$, 200.74$]
Financial Metrics affecting the LGND estimates:
- Negative: with PPE of 24.2 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of 1.31 <= 2.37
- Positive: 11.29 < Operating profit margin, % of 15.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of -3.74 <= -1.30
- Negative: Return on assets ratio (scaled to [-100,100]) of 7.39 <= 10.70
- Negative: negative Industry operating cash flow (median)
- Positive: -11.23 < Investing cash flow per share per price, % of -10.02
- Positive: 58.56 < Shareholder equity ratio, % of 65.18 <= 69.38
Short-term LGND quotes
Long-term LGND plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $133.44MM | $167.13MM | $268.09MM |
| Operating Expenses | $121.49MM | $189.74MM | $227.09MM |
| Operating Income | $11.94MM | $-22.61MM | $41.00MM |
| Non-Operating Income | $51.72MM | $25.12MM | $117.96MM |
| Interest Expense | $0.66MM | $3.04MM | $4.71MM |
| R&D Expense | $24.54MM | $21.43MM | $81.18MM |
| Income(Loss) | $63.66MM | $2.52MM | $158.96MM |
| Taxes | $9.84MM | $6.55MM | $34.51MM |
| Other Income(Loss) | $-1.67MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $52.15MM | $-4.03MM | $124.45MM |
| Stockholders Equity | $700.91MM | $830.44MM | $1,017.21MM |
| Inventory | $23.97MM | $14.11MM | $9.13MM |
| Assets | $787.22MM | $941.77MM | $1,560.64MM |
| Operating Cash Flow | $49.58MM | $97.05MM | $49.36MM |
| Capital expenditure | $53.85MM | $19.64MM | $0.45MM |
| Investing Cash Flow | $-11.68MM | $-143.66MM | $-377.32MM |
| Financing Cash Flow | $-59.95MM | $97.14MM | $428.22MM |
| Earnings Per Share** | $3.02 | $-0.22 | $6.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.